Jazz signs exclusive license agreement for Sumitomo’s narcolepsy drug
Jazz obtains development and commercialisation rights in the US, Europe and other territories, while Sumitomo Pharma retains rights…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 May 22
Jazz obtains development and commercialisation rights in the US, Europe and other territories, while Sumitomo Pharma retains rights…
05 May 22
The EC approval is supported by the Phase 2 ELARA trial, which showed that Kymriah has resulted in…
04 May 22
Cabometyx is an inhibitor of the tyrosine kinases c-Met and VEGFR2, discovered and developed by genomics-based drug discovery…
04 May 22
Darolutamide is an oral androgen receptor inhibitor (ARi), developed by the company in partnership with Orion Corp, and…
02 May 22
The US-based firm sought a variation to the CMA from the European Medicines Agency (EMA) to assess a…
02 May 22
The FDA approval is supported by safety and efficacy findings from the Phase III SELECT-AXIS 2 and Phase…
29 Apr 22
Camzyos is said to be the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source…
29 Apr 22
With the approval, Ultomiris becomes the first and only long-acting C5 complement inhibitor to be approved in the…
28 Apr 22
Vydura is indicated for acute treatment of migraine regardless of aura, and prophylaxis (prevention) of episodic migraine in…
28 Apr 22
The turnkey drug discovery solution leverages Valo’s AI-powered Opal Computational Platform and Charles River’s preclinical expertise